Document is current

Article History

Received: 26 November 2024

Accepted: 20 May 2025

First Online: 1 July 2025

Declarations

:

: R.L.A. and M.K.E. have grant support from Hillevax, Inc. and are consultants for that company. Baylor College of Medicine (R.L.A. and M.K.E. as inventors) has a patent for norovirus growth in human intestinal enteroids, and M.K.E. has a patent on methods and reagents to detect and characterize Norwalk virus and related viruses. The rest of the authors declare no competing interests.

: All methods were performed in accordance with relevant guidelines and regulations.

: RSV-positive samples were collected from patients enrolled at the Houston NVSN site only. They were obtained after written informed consent was obtained from the parent/guardian of the eligible children and age-appropriate assent from participating children. Institutional review board approval was obtained locally from Baylor College of Medicine (H-37691) and at the CDC.Norovirus-positive samples were collected as deidentified samples prior to disposal from a clinical laboratory or as residual samples collected in a clinical study. The latter samples were obtained after written informed consent was obtained from the participants. Institutional review board approval was obtained locally from Baylor College of Medicine for both study groups (H-8390, H-45026).